KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Short term Debt (2016 - 2025)

Boston Scientific's Short term Debt history spans 17 years, with the latest figure at $299.0 million for Q4 2025.

  • For Q4 2025, Short term Debt fell 83.18% year-over-year to $299.0 million; the TTM value through Dec 2025 reached $299.0 million, down 83.18%, while the annual FY2025 figure was $299.0 million, 83.18% down from the prior year.
  • Short term Debt for Q4 2025 was $299.0 million at Boston Scientific, up from $78.0 million in the prior quarter.
  • Across five years, Short term Debt topped out at $1.8 billion in Q4 2024 and bottomed at $23.0 million in Q1 2021.
  • The 5-year median for Short term Debt is $261.5 million (2021), against an average of $399.4 million.
  • The largest YoY upside for Short term Debt was 2123.08% in 2021 against a maximum downside of 97.71% in 2021.
  • A 5-year view of Short term Debt shows it stood at $289.0 million in 2021, then tumbled by 74.39% to $74.0 million in 2022, then soared by 617.57% to $531.0 million in 2023, then soared by 234.84% to $1.8 billion in 2024, then tumbled by 83.18% to $299.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Short term Debt are $299.0 million (Q4 2025), $78.0 million (Q3 2025), and $1.8 billion (Q4 2024).